Follow
Emilio Bria
Emilio Bria
Oncologia Medica, Fondazione Policlinico Universitario 'A. Gemelli', I.R.C.C.S., UniversitÓ
Verified email at unicatt.it
Title
Cited by
Cited by
Year
Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
F Roila, J Herrstedt, M Aapro, RJ Gralla, LH Einhorn, E Ballatori, E Bria, ...
Annals of Oncology 21, v232-v243, 2010
8702010
Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy
R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ...
JAMA oncology 4 (11), 1543-1552, 2018
6682018
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
6402020
Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials iná…
L Carbognin, S Pilotto, M Milella, V Vaccaro, M Brunelli, A Cali˛, ...
PloS one 10 (6), e0130142, 2015
5062015
Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negativeá…
FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ...
Journal of Clinical Oncology 40 (28), 3246, 2022
2302022
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients
E Bria, C Nistico, F Cuppone, P Carlini, M Ciccarese, M Milella, G Natoli, ...
Cancer 106 (11), 2337-2344, 2006
2072006
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials
E Bria, F Cuppone, M Fornier, C Nistic˛, P Carlini, M Milella, I Sperduti, ...
Breast cancer research and treatment 109, 231-239, 2008
1922008
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin‐remodelling genes as major players and a prognostic role forá…
M Simbolo, A Mafficini, KO Sikora, M Fassan, S Barbi, V Corbo, ...
The Journal of pathology 241 (4), 488-500, 2017
1892017
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospectiveá…
S Loibl, I Majewski, V Guarneri, V Nekljudova, E Holmes, E Bria, ...
Annals of Oncology 27 (8), 1519-1525, 2016
1852016
Patients’ perception of chemotherapy side effects: Expectations, doctor–patient communication and impact on quality of life–An Italian survey
D Lorusso, E Bria, A Costantini, M Di Maio, G Rosti, A Mancuso
European journal of cancer care 26 (2), e12618, 2017
1772017
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma
E Bajetta, M Di Bartolomeo, L Mariani, A Cassata, S Artale, S Frustaci, ...
Cancer 100 (2), 279-287, 2004
1622004
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
L Landi, R Chiari, M Tiseo, F D'IncÓ, C Dazzi, A Chella, A Delmonte, ...
Clinical cancer research 25 (24), 7312-7319, 2019
1502019
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer: Meta‐analysis of randomized trials
F Cuppone, E Bria, S Verma, KI Pritchard, S Gandhi, P Carlini, M Milella, ...
Cancer: Interdisciplinary International Journal of the American Cancerá…, 2008
1442008
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel
A Scarpa, K Sikora, M Fassan, AM Rachiglio, R Cappellesso, D Antonello, ...
PloS one 8 (11), e80478, 2013
1392013
The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer
R Iacovelli, C Ciccarese, E Bria, M Romano, E Fantinel, D Bimbatti, ...
Clinical genitourinary cancer 16 (3), e645-e653, 2018
1332018
Role of mTOR signaling in tumor microenvironment: an overview
F Conciatori, C Bazzichetto, I Falcone, S Pilotto, E Bria, F Cognetti, ...
International Journal of Molecular Sciences 19 (8), 2453, 2018
1322018
Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center
A Fabi, A Felici, G Metro, A Mirri, E Bria, S Telera, L Moscetti, M Russillo, ...
Journal of Experimental & Clinical Cancer Research 30, 1-7, 2011
1322011
Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress? A meta‐analysis of 20 phase 3 trials
E Bria, M Milella, A Gelibter, F Cuppone, MS Pino, EM Ruggeri, P Carlini, ...
Cancer: Interdisciplinary International Journal of the American Cancerá…, 2007
1302007
mTOR cross-talk in cancer and potential for combination therapy
F Conciatori, L Ciuffreda, C Bazzichetto, I Falcone, S Pilotto, E Bria, ...
Cancers 10 (1), 23, 2018
1282018
Physical activity and exercise in lung cancer care: will promises be fulfilled?
A Avancini, G Sartori, A Gkountakos, M Casali, I Trestini, D Tregnago, ...
The oncologist 25 (3), e555-e569, 2020
1242020
The system can't perform the operation now. Try again later.
Articles 1–20